ID   PK3CD_HUMAN             Reviewed;        1044 AA.
AC   O00329; A6NCG0; G1FFP1; O15445; Q5SR49;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 2.
DT   18-JUN-2025, entry version 220.
DE   RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform;
DE            Short=PI3-kinase subunit delta;
DE            Short=PI3K-delta;
DE            Short=PI3Kdelta;
DE            Short=PtdIns-3-kinase subunit delta;
DE            EC=2.7.1.137 {ECO:0000269|PubMed:9235916};
DE            EC=2.7.1.153 {ECO:0000269|PubMed:15135396};
DE   AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta;
DE            Short=PtdIns-3-kinase subunit p110-delta;
DE            Short=p110delta {ECO:0000303|PubMed:9235916};
GN   Name=PIK3CD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9113989; DOI=10.1073/pnas.94.9.4330;
RA   Vanhaesebroeck B.A.M., Welham M.J., Kotani K., Stein R., Warne P.H.,
RA   Zvelebil M.J., Higashi K., Volinia S., Downward J., Waterfield M.D.;
RT   "P110delta, a novel phosphoinositide 3-kinase in leukocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:4330-4335(1997).
RN   [2]
RP   SEQUENCE REVISION TO 675.
RA   Vanhaesebroeck B.A.M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=9235916; DOI=10.1074/jbc.272.31.19236;
RA   Chantry D., Vojtek A., Kashishian A., Holtzman D.A., Wood C., Gray P.W.,
RA   Cooper J.A., Hoekstra M.F.;
RT   "p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that
RT   associates with p85 and is expressed predominantly in leukocytes.";
RL   J. Biol. Chem. 272:19236-19241(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, INTERACTION WITH
RP   HRAS, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=22020336; DOI=10.1038/onc.2011.492;
RA   Fransson S., Uv A., Eriksson H., Andersson M.K., Wettergren Y., Bergo M.,
RA   Ejeskar K.;
RT   "p37delta is a new isoform of PI3K p110delta that increases cell
RT   proliferation and is overexpressed in tumors.";
RL   Oncogene 31:3277-3286(2012).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Jou S.-T., Chien Y.-H., Yang Y.-H., Shyur S.-D., Chou C.-C., Chiang B.-L.;
RT   "Variations in the human phosphoinositide-3-kinase p110 gene in children
RT   with primary B-cell immunodeficiency of unknown etiology.";
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15135396; DOI=10.1016/j.pep.2003.12.010;
RA   Meier T.I., Cook J.A., Thomas J.E., Radding J.A., Horn C., Lingaraj T.,
RA   Smith M.C.;
RT   "Cloning, expression, purification, and characterization of the human Class
RT   Ia phosphoinositide 3-kinase isoforms.";
RL   Protein Expr. Purif. 35:218-224(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 1031-1040, PHOSPHORYLATION AT SER-1039, AND MUTAGENESIS
RP   OF ARG-894 AND SER-1039.
RX   PubMed=10064595; DOI=10.1093/emboj/18.5.1292;
RA   Vanhaesebroeck B., Higashi K., Raven C., Welham M., Anderson S.,
RA   Brennan P., Ward S.G., Waterfield M.D.;
RT   "Autophosphorylation of p110 delta phosphoinositide 3-kinase: a new
RT   paradigm for the regulation of lipid kinases in vitro and in vivo.";
RL   EMBO J. 18:1292-1302(1999).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-524 AND SER-1039, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   FUNCTION IN T-CELLS, AND ACTIVITY REGULATION.
RX   PubMed=20081091; DOI=10.1182/blood-2009-07-232330;
RA   Soond D.R., Bjorgo E., Moltu K., Dale V.Q., Patton D.T., Torgersen K.M.,
RA   Galleway F., Twomey B., Clark J., Gaston J.S.H., Tasken K., Bunyard P.,
RA   Okkenhaug K.;
RT   "PI3K p110delta regulates T-cell cytokine production during primary and
RT   secondary immune responses in mice and humans.";
RL   Blood 115:2203-2213(2010).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=17290298; DOI=10.1038/nri2036;
RA   Rommel C., Camps M., Ji H.;
RT   "PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid
RT   arthritis and beyond?";
RL   Nat. Rev. Immunol. 7:191-201(2007).
RN   [13]
RP   REVIEW ON FUNCTION.
RX   PubMed=20940048; DOI=10.1016/j.cellsig.2010.10.002;
RA   Fung-Leung W.-P.;
RT   "Phosphoinositide 3-kinase delta (PI3Kdelta) in leukocyte signaling and
RT   function.";
RL   Cell. Signal. 23:603-608(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1039, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   INVOLVEMENT IN IMD14A, VARIANT IMD14A LYS-1021, AND CHARACTERIZATION OF
RP   VARIANT IMD14A LYS-1021.
RX   PubMed=24136356; DOI=10.1126/science.1243292;
RA   Angulo I., Vadas O., Garcon F., Banham-Hall E., Plagnol V., Leahy T.R.,
RA   Baxendale H., Coulter T., Curtis J., Wu C., Blake-Palmer K., Perisic O.,
RA   Smyth D., Maes M., Fiddler C., Juss J., Cilliers D., Markelj G.,
RA   Chandra A., Farmer G., Kielkowska A., Clark J., Kracker S., Debre M.,
RA   Picard C., Pellier I., Jabado N., Morris J.A., Barcenas-Morales G.,
RA   Fischer A., Stephens L., Hawkins P., Barrett J.C., Abinun M.,
RA   Clatworthy M., Durandy A., Doffinger R., Chilvers E.R., Cant A.J.,
RA   Kumararatne D., Okkenhaug K., Williams R.L., Condliffe A., Nejentsev S.;
RT   "Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory
RT   infection and airway damage.";
RL   Science 342:866-871(2013).
RN   [16]
RP   INVOLVEMENT IN ROCHIS, VARIANT ROCHIS 721-GLN--GLN-1044 DEL, AND
RP   CHARACTERIZATION OF VARIANT ROCHIS 721-GLN--GLN-1044 DEL.
RX   PubMed=29180244; DOI=10.1016/j.jaci.2017.10.033;
RA   Sharfe N., Karanxha A., Dadi H., Merico D., Chitayat D., Herbrick J.A.,
RA   Freeman S., Grinstein S., Roifman C.M.;
RT   "Dual loss of p110delta PI3-kinase and SKAP (KNSTRN) expression leads to
RT   combined immunodeficiency and multisystem syndromic features.";
RL   J. Allergy Clin. Immunol. 142:618-629(2018).
RN   [17]
RP   INVOLVEMENT IN IMD14B.
RX   PubMed=30040974; DOI=10.1016/j.jaci.2018.06.039;
RA   Sogkas G., Fedchenko M., Dhingra A., Jablonka A., Schmidt R.E.,
RA   Atschekzei F.;
RT   "Primary immunodeficiency disorder caused by phosphoinositide 3-kinase
RT   delta deficiency.";
RL   J. Allergy Clin. Immunol. 142:1650-1653(2018).
RN   [18]
RP   INVOLVEMENT IN IMD14B.
RX   PubMed=30336224; DOI=10.1016/j.jaci.2018.10.005;
RA   Cohen S.B., Bainter W., Johnson J.L., Lin T.Y., Wong J.C.Y., Wallace J.G.,
RA   Jones J., Qureshi S., Mir F., Qamar F., Cantley L.C., Geha R.S., Chou J.;
RT   "Human primary immunodeficiency caused by expression of a kinase-dead
RT   p110delta mutant.";
RL   J. Allergy Clin. Immunol. 143:797-799(2019).
CC   -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates
CC       phosphatidylinositol (PI) and its phosphorylated derivatives at
CC       position 3 of the inositol ring to produce 3-phosphoinositides
CC       (PubMed:9235916). Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-
CC       bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate
CC       (PIP3) (PubMed:15135396). PIP3 plays a key role by recruiting PH
CC       domain-containing proteins to the membrane, including AKT1 and PDPK1,
CC       activating signaling cascades involved in cell growth, survival,
CC       proliferation, motility and morphology. Mediates immune responses.
CC       Plays a role in B-cell development, proliferation, migration, and
CC       function. Required for B-cell receptor (BCR) signaling. Mediates B-cell
CC       proliferation response to anti-IgM, anti-CD40 and IL4 stimulation.
CC       Promotes cytokine production in response to TLR4 and TLR9. Required for
CC       antibody class switch mediated by TLR9. Involved in the antigen
CC       presentation function of B-cells. Involved in B-cell chemotaxis in
CC       response to CXCL13 and sphingosine 1-phosphate (S1P). Required for
CC       proliferation, signaling and cytokine production of naive, effector and
CC       memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates
CC       TCR signaling events at the immune synapse. Activation by TCR leads to
CC       antigen-dependent memory T-cell migration and retention to antigenic
CC       tissues. Together with PIK3CG participates in T-cell development.
CC       Contributes to T-helper cell expansion and differentiation. Required
CC       for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and
CC       S1PR1 and antigen dependent recruitment of T-cells. Together with
CC       PIK3CG is involved in natural killer (NK) cell development and
CC       migration towards the sites of inflammation. Participates in NK cell
CC       receptor activation. Plays a role in NK cell maturation and cytokine
CC       production. Together with PIK3CG is involved in neutrophil chemotaxis
CC       and extravasation. Together with PIK3CG participates in neutrophil
CC       respiratory burst. Plays important roles in mast-cell development and
CC       mast cell mediated allergic response. Involved in stem cell factor
CC       (SCF)-mediated proliferation, adhesion and migration. Required for
CC       allergen-IgE-induced degranulation and cytokine release. The lipid
CC       kinase activity is required for its biological function. Isoform 2 may
CC       be involved in stabilizing total RAS levels, resulting in increased ERK
CC       phosphorylation and increased PI3K activity.
CC       {ECO:0000269|PubMed:15135396, ECO:0000269|PubMed:20081091,
CC       ECO:0000269|PubMed:22020336, ECO:0000269|PubMed:9235916}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836,
CC         ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153;
CC         Evidence={ECO:0000269|PubMed:15135396};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293;
CC         Evidence={ECO:0000305|PubMed:15135396};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a
CC         1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP +
CC         H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216;
CC         EC=2.7.1.137; Evidence={ECO:0000269|PubMed:9235916};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710;
CC         Evidence={ECO:0000305|PubMed:9235916};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-
CC         3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2-
CC         (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo-
CC         inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137,
CC         ChEBI:CHEBI:83243, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000305|PubMed:15135396};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397;
CC         Evidence={ECO:0000305|PubMed:15135396};
CC   -!- ACTIVITY REGULATION: Activated by growth factors and cytokine receptors
CC       through a tyrosine-kinase-dependent mechanism. Activated by RAS.
CC       IC87114 inhibits lipid kinase activity and is selective in cells at
CC       doses up to 5-10 uM. IC87114 blocks T-cell receptor signaling in naive
CC       and memory T-cells and reduces cytokine production by memory T-cells.
CC       {ECO:0000269|PubMed:20081091}.
CC   -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate
CC       biosynthesis. {ECO:0000305|PubMed:15135396,
CC       ECO:0000305|PubMed:9113989}.
CC   -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CD and a p85 regulatory
CC       subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with ERAS (By
CC       similarity). Interacts with HRAS. {ECO:0000250,
CC       ECO:0000269|PubMed:22020336}.
CC   -!- INTERACTION:
CC       O00329; P01112: HRAS; NbExp=2; IntAct=EBI-718309, EBI-350145;
CC       O00329; P27986: PIK3R1; NbExp=9; IntAct=EBI-718309, EBI-79464;
CC       O00329; P27986-2: PIK3R1; NbExp=3; IntAct=EBI-718309, EBI-9090282;
CC       O00329; Q92569: PIK3R3; NbExp=6; IntAct=EBI-718309, EBI-79893;
CC       O00329-2; P01112: HRAS; NbExp=2; IntAct=EBI-6470902, EBI-350145;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:22020336}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=p110-delta;
CC         IsoId=O00329-1; Sequence=Displayed;
CC       Name=2; Synonyms=p37-delta;
CC         IsoId=O00329-2; Sequence=VSP_044409, VSP_044410;
CC   -!- TISSUE SPECIFICITY: In humans, the highest levels of expression are
CC       seen in peripheral blood mononuclear cells, spleen, and thymus, and low
CC       levels of expression in testes, uterus, colon, and small intestine but
CC       not in other tissues examined including prostate, heart, brain, and
CC       liver (PubMed:9235916). Isoform 2 is expressed in normal thymus, lung
CC       and spleen tissues, and is detected at low levels in normal lysates
CC       from colon and ovarian biopsies, at elevated levels in lysates from
CC       colorectal tumors and is abundantly expressed in some ovarian tumors
CC       (at protein level). Both isoform 1 and isoform 2 are widely expressed.
CC       Isoform 1 is expressed predominantly in leukocytes.
CC       {ECO:0000269|PubMed:22020336, ECO:0000269|PubMed:9235916}.
CC   -!- PTM: Autophosphorylation on Ser-1039 results in the almost complete
CC       inactivation of the lipid kinase activity.
CC       {ECO:0000269|PubMed:10064595}.
CC   -!- DISEASE: Immunodeficiency 14A with lymphoproliferation, autosomal
CC       dominant (IMD14A) [MIM:615513]: A disorder characterized by recurrent
CC       respiratory infections, progressive airway damage, lymphopenia,
CC       increased circulating transitional B cells, increased immunoglobulin M,
CC       reduced immunoglobulin G2 levels in serum, and impaired vaccine
CC       responses. {ECO:0000269|PubMed:24136356}. Note=The disease is caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Immunodeficiency 14B, autosomal recessive (IMD14B)
CC       [MIM:619281]: An autosomal recessive, primary immunodeficiency
CC       characterized by recurrent sinopulmonary infections apparent in early
CC       childhood. Some patients may develop inflammatory bowel disease or
CC       osteomyelitis. Immunological features include hypogammaglobulinemia,
CC       decreased levels of B cells, and evidence of impaired immune-mediated
CC       cytotoxicity and defective T-cell function.
CC       {ECO:0000269|PubMed:30040974, ECO:0000269|PubMed:30336224}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Roifman-Chitayat syndrome (ROCHIS) [MIM:613328]: An autosomal
CC       recessive digenic disorder characterized by global developmental delay,
CC       variable neurologic features such as seizures and ataxia, optic
CC       atrophy, dysmorphic facial features, distal skeletal anomalies, and
CC       recurrent invasive infections due to combined immunodeficiency.
CC       {ECO:0000269|PubMed:29180244}. Note=The disease is caused by variants
CC       affecting distinct genetic loci, including the gene represented in this
CC       entry. Caused by the simultaneous occurrence of homozygous mutations in
CC       PIK3CD and KNSTRN. {ECO:0000269|PubMed:29180244}.
CC   -!- MISCELLANEOUS: IC87114 inhibitor reduces passive cutaneous anaphylaxis,
CC       attenuates allergic airway inflammation and hyperresponsiveness and
CC       allergen induced rhinitis response. Inhibitors may have therapeutic
CC       potential for the treatment of immune system-mediated diseases such as
CC       auto-immune diseases, inflammation and allergy (PubMed:17290298,
CC       PubMed:20940048).
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00877, ECO:0000255|PROSITE-ProRule:PRU00879,
CC       ECO:0000255|PROSITE-ProRule:PRU00880}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/46261/PIK3CD";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y10055; CAA71149.2; -; mRNA.
DR   EMBL; U86453; AAC25677.1; -; mRNA.
DR   EMBL; JN190435; AEK81610.1; -; mRNA.
DR   EMBL; DQ263594; ABB83814.1; -; mRNA.
DR   EMBL; AL691449; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC132919; AAI32920.1; -; mRNA.
DR   EMBL; BC132921; AAI32922.1; -; mRNA.
DR   CCDS; CCDS104.1; -. [O00329-1]
DR   RefSeq; NP_005017.3; NM_005026.3. [O00329-1]
DR   RefSeq; XP_006710750.1; XM_006710687.3. [O00329-1]
DR   RefSeq; XP_006710752.1; XM_006710689.3. [O00329-1]
DR   RefSeq; XP_047278506.1; XM_047422550.1. [O00329-1]
DR   RefSeq; XP_047278507.1; XM_047422551.1. [O00329-1]
DR   RefSeq; XP_047278508.1; XM_047422552.1. [O00329-1]
DR   RefSeq; XP_047278509.1; XM_047422553.1. [O00329-1]
DR   RefSeq; XP_047278510.1; XM_047422554.1. [O00329-1]
DR   RefSeq; XP_047278511.1; XM_047422555.1. [O00329-1]
DR   RefSeq; XP_047278512.1; XM_047422556.1. [O00329-1]
DR   RefSeq; XP_047278513.1; XM_047422557.1. [O00329-1]
DR   RefSeq; XP_047278514.1; XM_047422558.1. [O00329-1]
DR   RefSeq; XP_047278515.1; XM_047422559.1. [O00329-1]
DR   RefSeq; XP_047278516.1; XM_047422560.1. [O00329-1]
DR   PDB; 5DXU; X-ray; 2.64 A; A=2-1044.
DR   PDB; 5M6U; X-ray; 2.85 A; A=17-1027.
DR   PDB; 5T8F; X-ray; 2.91 A; A=17-1031.
DR   PDB; 5UBT; X-ray; 2.83 A; A=17-1029.
DR   PDB; 5VLR; X-ray; 2.80 A; A=17-1029.
DR   PDB; 6G6W; X-ray; 2.72 A; A=1-1044.
DR   PDB; 6OCO; X-ray; 2.58 A; A=17-1031.
DR   PDB; 6OCU; X-ray; 2.77 A; A=1-1044.
DR   PDB; 6PYR; X-ray; 2.21 A; A=17-1034.
DR   PDB; 6PYU; X-ray; 2.54 A; A=17-1034.
DR   PDB; 7JIS; X-ray; 2.42 A; A=17-1034.
DR   PDB; 7LM2; X-ray; 2.79 A; A=12-1031.
DR   PDB; 7LQ1; X-ray; 2.96 A; A=1-1044.
DR   PDB; 8BCY; X-ray; 2.43 A; A=17-1034.
DR   PDB; 8S3R; X-ray; 2.28 A; A=17-1034.
DR   PDB; 9GCF; X-ray; 2.89 A; A=1-1044.
DR   PDB; 9GDI; X-ray; 2.81 A; A=1-1044.
DR   PDBsum; 5DXU; -.
DR   PDBsum; 5M6U; -.
DR   PDBsum; 5T8F; -.
DR   PDBsum; 5UBT; -.
DR   PDBsum; 5VLR; -.
DR   PDBsum; 6G6W; -.
DR   PDBsum; 6OCO; -.
DR   PDBsum; 6OCU; -.
DR   PDBsum; 6PYR; -.
DR   PDBsum; 6PYU; -.
DR   PDBsum; 7JIS; -.
DR   PDBsum; 7LM2; -.
DR   PDBsum; 7LQ1; -.
DR   PDBsum; 8BCY; -.
DR   PDBsum; 8S3R; -.
DR   PDBsum; 9GCF; -.
DR   PDBsum; 9GDI; -.
DR   AlphaFoldDB; O00329; -.
DR   SMR; O00329; -.
DR   BioGRID; 111311; 21.
DR   ComplexPortal; CPX-5978; Phosphatidylinositol 3-kinase complex class IA, p110delta/p55gamma.
DR   ComplexPortal; CPX-5980; Phosphatidylinositol 3-kinase complex class IA, p110delta/p85beta.
DR   ComplexPortal; CPX-5983; Phosphatidylinositol 3-kinase complex class IA, p110delta/p85alpha.
DR   ComplexPortal; CPX-5984; Phosphatidylinositol 3-kinase complex class IA, p110delta/p55alpha.
DR   ComplexPortal; CPX-5985; Phosphatidylinositol 3-kinase complex class IA, p110delta/p50alpha.
DR   CORUM; O00329; -.
DR   FunCoup; O00329; 2347.
DR   IntAct; O00329; 13.
DR   MINT; O00329; -.
DR   STRING; 9606.ENSP00000366563; -.
DR   BindingDB; O00329; -.
DR   ChEMBL; CHEMBL3130; -.
DR   DrugBank; DB06831; 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE.
DR   DrugBank; DB15407; Acalisib.
DR   DrugBank; DB16879; AMG-319.
DR   DrugBank; DB11666; Buparlisib.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB13051; CH-5132799.
DR   DrugBank; DB12483; Copanlisib.
DR   DrugBank; DB16137; Dezapelisib.
DR   DrugBank; DB11952; Duvelisib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB09054; Idelalisib.
DR   DrugBank; DB16217; Leniolisib.
DR   DrugBank; DB14867; Parsaclisib.
DR   DrugBank; DB15295; Tenalisib.
DR   DrugBank; DB05552; TG100-115.
DR   DrugBank; DB14989; Umbralisib.
DR   DrugBank; DB08059; Wortmannin.
DR   DrugBank; DB05241; XL765.
DR   DrugCentral; O00329; -.
DR   GuidetoPHARMACOLOGY; 2155; -.
DR   SwissLipids; SLP:000000908; -.
DR   GlyCosmos; O00329; 1 site, 1 glycan.
DR   GlyGen; O00329; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; O00329; -.
DR   PhosphoSitePlus; O00329; -.
DR   BioMuta; PIK3CD; -.
DR   CPTAC; CPTAC-1213; -.
DR   CPTAC; CPTAC-3075; -.
DR   jPOST; O00329; -.
DR   MassIVE; O00329; -.
DR   PaxDb; 9606-ENSP00000366563; -.
DR   PeptideAtlas; O00329; -.
DR   ProteomicsDB; 47850; -. [O00329-1]
DR   Pumba; O00329; -.
DR   Antibodypedia; 4215; 594 antibodies from 39 providers.
DR   DNASU; 5293; -.
DR   Ensembl; ENST00000377346.9; ENSP00000366563.4; ENSG00000171608.18. [O00329-1]
DR   Ensembl; ENST00000481137.2; ENSP00000513886.1; ENSG00000171608.18. [O00329-2]
DR   Ensembl; ENST00000698712.1; ENSP00000513889.1; ENSG00000171608.18. [O00329-1]
DR   Ensembl; ENST00000698713.1; ENSP00000513890.1; ENSG00000171608.18. [O00329-1]
DR   GeneID; 5293; -.
DR   KEGG; hsa:5293; -.
DR   MANE-Select; ENST00000377346.9; ENSP00000366563.4; NM_005026.5; NP_005017.3.
DR   UCSC; uc001aqb.5; human. [O00329-1]
DR   AGR; HGNC:8977; -.
DR   CTD; 5293; -.
DR   DisGeNET; 5293; -.
DR   GeneCards; PIK3CD; -.
DR   GeneReviews; PIK3CD; -.
DR   HGNC; HGNC:8977; PIK3CD.
DR   HPA; ENSG00000171608; Group enriched (bone marrow, intestine, lymphoid tissue).
DR   MalaCards; PIK3CD; -.
DR   MIM; 602839; gene.
DR   MIM; 613328; phenotype.
DR   MIM; 615513; phenotype.
DR   MIM; 619281; phenotype.
DR   OpenTargets; ENSG00000171608; -.
DR   Orphanet; 397596; Activated PI3K-delta syndrome.
DR   Orphanet; 33110; Autosomal non-syndromic agammaglobulinemia.
DR   Orphanet; 221139; Combined immunodeficiency with facio-oculo-skeletal anomalies.
DR   VEuPathDB; HostDB:ENSG00000171608; -.
DR   eggNOG; KOG0904; Eukaryota.
DR   GeneTree; ENSGT00940000159079; -.
DR   InParanoid; O00329; -.
DR   OMA; CCEPQIT; -.
DR   OrthoDB; 67688at2759; -.
DR   PAN-GO; O00329; 8 GO annotations based on evolutionary models.
DR   PhylomeDB; O00329; -.
DR   BioCyc; MetaCyc:ENSG00000171608-MONOMER; -.
DR   BRENDA; 2.7.1.137; 2681.
DR   BRENDA; 2.7.1.153; 2681.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; O00329; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K).
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-9680350; Signaling by CSF1 (M-CSF) in myeloid cells.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   Reactome; R-HSA-9856530; High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells.
DR   Reactome; R-HSA-9927354; Co-stimulation by ICOS.
DR   SignaLink; O00329; -.
DR   SIGNOR; O00329; -.
DR   UniPathway; UPA00220; -.
DR   BioGRID-ORCS; 5293; 24 hits in 1165 CRISPR screens.
DR   ChiTaRS; PIK3CD; human.
DR   GeneWiki; P110%CE%B4; -.
DR   GenomeRNAi; 5293; -.
DR   Pharos; O00329; Tclin.
DR   PRO; PR:O00329; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O00329; protein.
DR   Bgee; ENSG00000171608; Expressed in granulocyte and 183 other cell types or tissues.
DR   ExpressionAtlas; O00329; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; IPI:ComplexPortal.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IBA:GO_Central.
DR   GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0035754; P:B cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; NAS:ComplexPortal.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0006955; P:immune response; NAS:ComplexPortal.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0002551; P:mast cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0043303; P:mast cell degranulation; TAS:UniProtKB.
DR   GO; GO:0060374; P:mast cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030101; P:natural killer cell activation; TAS:UniProtKB.
DR   GO; GO:0035747; P:natural killer cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0001779; P:natural killer cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; TAS:UniProtKB.
DR   GO; GO:0072672; P:neutrophil extravasation; TAS:UniProtKB.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:CAFA.
DR   GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:CACAO.
DR   GO; GO:0001819; P:positive regulation of cytokine production; TAS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IGI:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IGI:BHF-UCL.
DR   GO; GO:1905278; P:positive regulation of epithelial tube formation; IGI:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CACAO.
DR   GO; GO:0033031; P:positive regulation of neutrophil apoptotic process; IMP:CAFA.
DR   GO; GO:0006468; P:protein phosphorylation; NAS:UniProtKB.
DR   GO; GO:0002679; P:respiratory burst involved in defense response; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; TAS:UniProtKB.
DR   GO; GO:0010818; P:T cell chemotaxis; TAS:UniProtKB.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0030217; P:T cell differentiation; TAS:UniProtKB.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; IGI:BHF-UCL.
DR   CDD; cd08693; C2_PI3K_class_I_beta_delta; 1.
DR   CDD; cd05174; PI3Kc_IA_delta; 1.
DR   FunFam; 1.10.1070.11:FF:000001; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1.
DR   FunFam; 1.25.40.70:FF:000008; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1.
DR   FunFam; 2.60.40.150:FF:000046; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1.
DR   FunFam; 3.10.20.770:FF:000002; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit; 1.
DR   FunFam; 3.30.1010.10:FF:000005; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta; 1.
DR   Gene3D; 3.10.20.770; -; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1.
DR   Gene3D; 3.30.1010.10; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 4; 1.
DR   Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR002420; PI3K-type_C2_dom.
DR   InterPro; IPR003113; PI3K_ABD.
DR   InterPro; IPR001263; PI3K_accessory_dom.
DR   InterPro; IPR042236; PI3K_accessory_sf.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR037703; PI3Kdelta_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR10048:SF35; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM; 1.
DR   PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF02192; PI3K_p85B; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00143; PI3K_p85B; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS51547; C2_PI3K; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51544; PI3K_ABD; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
DR   neXtProt; NX_O00329; -.
DR   PharmGKB; PA33310; -.
DR   TreeFam; TF102031; -.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; ATP-binding;
KW   Chemotaxis; Cytoplasm; Differentiation; Direct protein sequencing;
KW   Disease variant; Immunity; Inflammatory response; Innate immunity; Kinase;
KW   Lipid metabolism; Nucleotide-binding; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Transferase.
FT   CHAIN           1..1044
FT                   /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase
FT                   catalytic subunit delta isoform"
FT                   /id="PRO_0000088790"
FT   DOMAIN          16..105
FT                   /note="PI3K-ABD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00877"
FT   DOMAIN          187..278
FT                   /note="PI3K-RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00879"
FT   DOMAIN          319..476
FT                   /note="C2 PI3K-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00880"
FT   DOMAIN          497..674
FT                   /note="PIK helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00878"
FT   DOMAIN          745..1027
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          287..312
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          751..757
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          890..898
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          909..935
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   MOD_RES         524
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         1039
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:10064595,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         201..300
FT                   /note="ESFTFQVSTKDVPLALMACALRKKATVFRQPLVEQPEDYTLQVNGRHEYLYG
FT                   SYPLCQFQYICSCLHSGLTPHLTMVHSSSILAMRDEQSNPAPQVQKPR -> VSPCVAC
FT                   GIQAALSMGSTSSVKLLSHPQAPLPQWHQMVFARCLCMCGAQLNVPPGELHLPGVHQGR
FT                   AAGADGLCPAEEGHSVPAAAGGAAGRLHAAGERQ (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:22020336"
FT                   /id="VSP_044409"
FT   VAR_SEQ         302..1044
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:22020336"
FT                   /id="VSP_044410"
FT   VARIANT         721..1044
FT                   /note="Missing (in ROCHIS; no protein can be detected by
FT                   Western blot in patient cells)"
FT                   /evidence="ECO:0000269|PubMed:29180244"
FT                   /id="VAR_085590"
FT   VARIANT         1021
FT                   /note="E -> K (in IMD14A; results in gain of function
FT                   causing enhanced membrane association and kinase activity;
FT                   dbSNP:rs397518423)"
FT                   /evidence="ECO:0000269|PubMed:24136356"
FT                   /id="VAR_070918"
FT   MUTAGEN         894
FT                   /note="R->P: Abolishes lipid and protein kinase
FT                   activities."
FT                   /evidence="ECO:0000269|PubMed:10064595"
FT   MUTAGEN         1039
FT                   /note="S->A: Abolishes autophosphorylation, no effect on
FT                   lipid kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10064595"
FT   MUTAGEN         1039
FT                   /note="S->D,E: Abolishes autophosphorylation, reduced lipid
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:10064595"
FT   CONFLICT        253
FT                   /note="S -> N (in Ref. 3; AAC25677)"
FT                   /evidence="ECO:0000305"
FT   TURN            13..15
FT                   /evidence="ECO:0007829|PDB:7LM2"
FT   STRAND          19..25
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          31..37
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           42..53
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           59..61
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           65..67
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          68..74
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          79..81
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:6OCO"
FT   HELIX           89..92
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          94..103
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           108..120
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          121..123
FT                   /evidence="ECO:0007829|PDB:8BCY"
FT   HELIX           126..129
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           134..155
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           159..166
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          189..196
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          202..208
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           213..225
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           236..238
FT                   /evidence="ECO:0007829|PDB:7JIS"
FT   STRAND          239..243
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   TURN            244..247
FT                   /evidence="ECO:0007829|PDB:7LQ1"
FT   STRAND          248..250
FT                   /evidence="ECO:0007829|PDB:6PYU"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           256..258
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           260..268
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          273..278
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           279..286
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           316..318
FT                   /evidence="ECO:0007829|PDB:7JIS"
FT   STRAND          321..332
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          339..349
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          352..355
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          366..368
FT                   /evidence="ECO:0007829|PDB:7LQ1"
FT   STRAND          370..380
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           381..383
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          389..397
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          416..426
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          430..432
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          435..440
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          455..457
FT                   /evidence="ECO:0007829|PDB:6OCU"
FT   TURN            465..467
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          470..475
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          479..481
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           488..495
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           505..515
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          517..519
FT                   /evidence="ECO:0007829|PDB:5M6U"
FT   HELIX           525..533
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           535..541
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           543..545
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           546..552
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           558..570
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           576..582
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           590..600
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           605..617
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           618..621
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          623..626
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           628..639
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           641..652
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   TURN            653..656
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   TURN            658..660
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           661..673
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           676..703
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          704..706
FT                   /evidence="ECO:0007829|PDB:5VLR"
FT   HELIX           708..719
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           722..728
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          729..732
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          739..741
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           746..748
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          753..756
FT                   /evidence="ECO:0007829|PDB:8BCY"
FT   STRAND          759..764
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           770..772
FT                   /evidence="ECO:0007829|PDB:6PYU"
FT   STRAND          774..782
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           785..803
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          815..819
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          822..826
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          829..833
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           834..839
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           854..862
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           865..867
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           868..889
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   TURN            896..898
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          899..902
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          907..909
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           936..942
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   TURN            943..945
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           950..969
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           971..981
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           982..984
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   STRAND          989..991
FT                   /evidence="ECO:0007829|PDB:5VLR"
FT   HELIX           992..1001
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   TURN            1002..1005
FT                   /evidence="ECO:0007829|PDB:6PYR"
FT   HELIX           1008..1031
FT                   /evidence="ECO:0007829|PDB:6PYR"
SQ   SEQUENCE   1044 AA;  119479 MW;  A38B5D1A1081A3D0 CRC64;
     MPPGVDCPME FWTKEENQSV VVDFLLPTGV YLNFPVSRNA NLSTIKQLLW HRAQYEPLFH
     MLSGPEAYVF TCINQTAEQQ ELEDEQRRLC DVQPFLPVLR LVAREGDRVK KLINSQISLL
     IGKGLHEFDS LCDPEVNDFR AKMCQFCEEA AARRQQLGWE AWLQYSFPLQ LEPSAQTWGP
     GTLRLPNRAL LVNVKFEGSE ESFTFQVSTK DVPLALMACA LRKKATVFRQ PLVEQPEDYT
     LQVNGRHEYL YGSYPLCQFQ YICSCLHSGL TPHLTMVHSS SILAMRDEQS NPAPQVQKPR
     AKPPPIPAKK PSSVSLWSLE QPFRIELIQG SKVNADERMK LVVQAGLFHG NEMLCKTVSS
     SEVSVCSEPV WKQRLEFDIN ICDLPRMARL CFALYAVIEK AKKARSTKKK SKKADCPIAW
     ANLMLFDYKD QLKTGERCLY MWPSVPDEKG ELLNPTGTVR SNPNTDSAAA LLICLPEVAP
     HPVYYPALEK ILELGRHSEC VHVTEEEQLQ LREILERRGS GELYEHEKDL VWKLRHEVQE
     HFPEALARLL LVTKWNKHED VAQMLYLLCS WPELPVLSAL ELLDFSFPDC HVGSFAIKSL
     RKLTDDELFQ YLLQLVQVLK YESYLDCELT KFLLDRALAN RKIGHFLFWH LRSEMHVPSV
     ALRFGLILEA YCRGSTHHMK VLMKQGEALS KLKALNDFVK LSSQKTPKPQ TKELMHLCMR
     QEAYLEALSH LQSPLDPSTL LAEVCVEQCT FMDSKMKPLW IMYSNEEAGS GGSVGIIFKN
     GDDLRQDMLT LQMIQLMDVL WKQEGLDLRM TPYGCLPTGD RTGLIEVVLR SDTIANIQLN
     KSNMAATAAF NKDALLNWLK SKNPGEALDR AIEEFTLSCA GYCVATYVLG IGDRHSDNIM
     IRESGQLFHI DFGHFLGNFK TKFGINRERV PFILTYDFVH VIQQGKTNNS EKFERFRGYC
     ERAYTILRRH GLLFLHLFAL MRAAGLPELS CSKDIQYLKD SLALGKTEEE ALKHFRVKFN
     EALRESWKTK VNWLAHNVSK DNRQ
//
